A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Feb 2019
At a glance
- Drugs ARQ-151 (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Arcutis Pharmaceuticals
- 29 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 09 Oct 2018 Status changed from not yet recruiting to recruiting.
- 24 Aug 2018 New trial record